{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:57:27Z","timestamp":1777431447164,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40290-025-00587-6","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T04:58:42Z","timestamp":1758344322000},"page":"445-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Utilization, Reimbursement, and Cost of Targeted Therapies for Duchenne Muscular Dystrophy (DMD) in US Medicaid Programs: A Descriptive Trend Analysis from 2017 to 2022"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1771-506X","authenticated-orcid":false,"given":"Yazeed","family":"Ghawaa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff Jianfei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"587_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/978-3-319-17362-7_2","volume-title":"Muscular Dystrophy: a concise guide","author":"RA Huml","year":"2015","unstructured":"Huml RA. Muscular dystrophy: historical background and types. In: Raymond AH, editor. Muscular Dystrophy: a concise guide. Berlin: Springer; 2015. p. 5\u20137."},{"issue":"3","key":"587_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(18)30024-3.","journal-title":"Lancet Neurol"},{"issue":"3","key":"587_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11897-020-00456-0","volume":"17","author":"JA Shih","year":"2020","unstructured":"Shih JA, Folch A, Wong BL. Duchenne muscular dystrophy: the heart of the matter. Curr Heart Fail Rep. 2020;17(3):57\u201366. https:\/\/doi.org\/10.1007\/s11897-020-00456-0.","journal-title":"Curr Heart Fail Rep"},{"issue":"10","key":"587_CR4","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1089\/hum.2018.151","volume":"29","author":"F Galli","year":"2018","unstructured":"Galli F, Bragg L, Meggiolaro L, Rossi M, Caffarini M, Naz N, et al. Gene and cell therapy for muscular dystrophies: are we getting there? Hum Gene Ther. 2018;29(10):1098\u2013105. https:\/\/doi.org\/10.1089\/hum.2018.151.","journal-title":"Hum Gene Ther"},{"key":"587_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KRQ Lim","year":"2017","unstructured":"Lim KRQ, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017;11:533\u201345. https:\/\/doi.org\/10.2147\/DDDT.S97635.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"587_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14712598.2017.1250880","volume":"17","author":"S Fletcher","year":"2017","unstructured":"Fletcher S, Bellgard MI, Price L, Akkari AP, Wilton SD. Translational development of splice-modifying antisense oligomers. Expert Opin Biol Ther. 2017;17(1):15\u201330. https:\/\/doi.org\/10.1080\/14712598.2017.1250880.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"587_CR7","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s13311-023-01423-y","volume":"20","author":"ES D\u2019Ambrosis","year":"2023","unstructured":"D\u2019Ambrosis ES, Mendell JR. Evolving therapeutic options for the treatment of Duchenne Muscular Dystrophy. Neurotherapeutics. 2023;20(6):1669\u201381. https:\/\/doi.org\/10.1007\/s13311-023-01423-y.","journal-title":"Neurotherapeutics"},{"issue":"12","key":"587_CR8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51237","volume":"15","author":"ME Vasterling","year":"2023","unstructured":"Vasterling ME, Maitski RJ, Davis BA, Barnes JE, Kelkar RA, Klapper RJ, et al. Amondys 45 (Casimersen), a novel antisense phosphorodiamidate morpholino oligomer: clinical considerations for treatment in Duchenne Muscular Dystrophy. Cureus. 2023;15(12):e51237. https:\/\/doi.org\/10.7759\/cureus.51237.","journal-title":"Cureus."},{"issue":"7","key":"587_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s10198-020-01197-6","volume":"21","author":"D Flores","year":"2020","unstructured":"Flores D, Ribate MP, Montolio M, Ramos FJ, G\u00f3mez M, Garc\u00eda CB. Quantifying the economic impact of caregiving for Duchenne muscular dystrophy (DMD) in Spain. Eur J Health Econ. 2020;21(7):1015\u201323. https:\/\/doi.org\/10.1007\/s10198-020-01197-6.","journal-title":"Eur J Health Econ"},{"issue":"10","key":"587_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/dmcn.13934","volume":"60","author":"E Landfeldt","year":"2018","unstructured":"Landfeldt E, Edstr\u00f6m J, Buccella F, Kirschner J, Lochm\u00fcller H. Duchenne muscular dystrophy and caregiver burden: a systematic review. Dev Med Child Neurol. 2018;60(10):987\u201396. https:\/\/doi.org\/10.1111\/dmcn.13934.","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"587_CR11","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/00004703-200612000-00003","volume":"27","author":"VJ Hinton","year":"2006","unstructured":"Hinton VJ, Nereo NE, Fee RJ, Cyrulnik SE. Social behavior problems in boys with Duchenne muscular dystrophy. J Dev Behav Pediatr. 2006;27(6):470\u20136. https:\/\/doi.org\/10.1097\/00004703-200612000-00003.","journal-title":"J Dev Behav Pediatr"},{"issue":"6","key":"587_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","volume":"83","author":"E Landfeldt","year":"2014","unstructured":"Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83(6):529\u201336. https:\/\/doi.org\/10.1212\/WNL.0000000000000669.","journal-title":"Neurology"},{"issue":"6","key":"587_CR13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.18553\/jmcp.2017.23.6.633","volume":"23","author":"S Thayer","year":"2017","unstructured":"Thayer S, Bell C, McDonald CM. The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States. J Manag Care Spec Pharm. 2017;23(6):633\u201341. https:\/\/doi.org\/10.18553\/jmcp.2017.23.6.633.","journal-title":"J Manag Care Spec Pharm"},{"key":"587_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.vhri.2023.08.004","volume":"38","author":"Z Shehata","year":"2023","unstructured":"Shehata Z, Metry A, Rabea H, Elsherif R, Abdelrahim M, Dawoud D. Early cost-utility analysis of ataluren and eteplirsen in the treatment of Duchenne Muscular Dystrophy in Egypt. Value Health Reg Issues. 2023;38:109\u201317. https:\/\/doi.org\/10.1016\/j.vhri.2023.08.004.","journal-title":"Value Health Reg Issues"},{"key":"587_CR15","unstructured":"Lin G, Agboola F, Otuonya I. Deflazacort, eteplirsen, and golodirsen for Duchenne muscular dystrophy: effectiveness and value-evidence report. Institute for Clinical and Economic Review; 2019. 115-33. ICER_DMD-Final-Report_081519-2-1.pdf. Accessed 5 Aug 2025"},{"key":"587_CR16","unstructured":"Fidler B. FDA gives speedy approval to another Duchenne drug. BioPharma Dive. https:\/\/www.biopharmadive.com\/news\/viltolarsen-duchenne-fda-approval-ns-pharma\/583410\/. Accessed 5 Aug 2025."},{"key":"587_CR17","unstructured":"Amondys 45\u00ae (casimersen) [Sarepta Therapeutics]. New Drug Fact Blast: Clinical Services. Conduent Business Services, LLC. 2021. Available at: amondys-45-casimersen-ndfb_mo.pdf. Accessed August 5, 2025."},{"issue":"1","key":"587_CR18","doi-asserted-by":"publisher","first-page":"e2353094","DOI":"10.1001\/jamanetworkopen.2023.53094","volume":"7","author":"D Hong","year":"2024","unstructured":"Hong D, Avorn J, Wyss R, Kesselheim AS. Characteristics of patients receiving novel muscular dystrophy drugs in trials vs routine care. JAMA Netw Open. 2024;7(1):e2353094. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.53094.","journal-title":"JAMA Netw Open"},{"issue":"13","key":"587_CR19","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2024.2776","volume":"331","author":"L Bendicksen","year":"2024","unstructured":"Bendicksen L, Kesselheim AS, Rome BN. Spending on targeted therapies for Duchenne muscular dystrophy. JAMA. 2024;331(13):1151\u20133. https:\/\/doi.org\/10.1001\/jama.2024.2776.","journal-title":"JAMA"},{"key":"587_CR20","unstructured":"Eteplirsen. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations [internet]. Silver Spring (MD): FDA; [cited November 7, 2024]. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/patent_info.cfm?Product_No=001&Appl_No=206488&Appl_type=N."},{"key":"587_CR21","unstructured":"Golodirsen. U.S. Food and Drug Administration. Orange book: approved drug products with therapeutic equivalence evaluations. Silver Spring (MD): FDA; [cited November 7, 2024]. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/patent_info.cfm?Product_No=001&Appl_No=211970&Appl_type=N."},{"key":"587_CR22","unstructured":"Viltolarsen. U.S. Food and Drug Administration. Orange book: approved drug products with therapeutic equivalence evaluations. Silver Spring (MD): FDA; [cited November 7, 2024]. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/patent_info.cfm?Product_No=001&Appl_No=212154&Appl_type=N."},{"key":"587_CR23","unstructured":"Casimersen. U.S. Food and Drug Administration. Orange book: approved drug products with therapeutic equivalence evaluations. Silver Spring (MD): FDA; [cited November 7, 2024]. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/patent_info.cfm?Product_No=001&Appl_No=213026&Appl_type=N."},{"key":"587_CR24","unstructured":"Medicaid Drug Rebate Program Data | Medicaid. Medicaid.gov. 2022. https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/medicaid-drug-rebate-program\/medicaid-drug-rebate-program-data\/index.html. Accessed 18 Mar 2023."},{"issue":"9","key":"587_CR25","doi-asserted-by":"publisher","first-page":"671","DOI":"10.18553\/jmcp.2010.16.9.671","volume":"16","author":"B Bian","year":"2010","unstructured":"Bian B, Kelton CML, Guo JJ, Wigle PR. ACE inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008. J Manag Care Pharm. 2010;16(9):671\u20139. https:\/\/doi.org\/10.18553\/jmcp.2010.16.9.671.","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"587_CR26","first-page":"140","volume":"4","author":"SF Chiu","year":"2011","unstructured":"Chiu SF, Kelton CML, Guo JJ, Wigle PR, Lin AC, Szeinbach SL. Utilization, spending, and price trends for short- and long-acting Beta-agonists and inhaled corticosteroids in the medicaid program, 1991\u20132010. Am Health Drug Benef. 2011;4(3):140\u20139.","journal-title":"Am Health Drug Benef"},{"issue":"4","key":"587_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1345\/aph.1Q618","volume":"46","author":"E Gorevski","year":"2012","unstructured":"Gorevski E, Bian B, Kelton CML, Martin Boone JE, Guo JJ. Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991\u20132009. Ann Pharmacother. 2012;46(4):503\u201312. https:\/\/doi.org\/10.1345\/aph.1Q618.","journal-title":"Ann Pharmacother"},{"issue":"7","key":"587_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1089\/hum.2012.099","volume":"23","author":"H Foster","year":"2012","unstructured":"Foster H, Popplewell L, Dickson G. Genetic therapeutic approaches for duchenne muscular dystrophy. Hum Gene Ther. 2012;23(7):676\u201387. https:\/\/doi.org\/10.1089\/hum.2012.099.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"587_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/jamaneurol.2015.4011","volume":"73","author":"RD Jacobson","year":"2016","unstructured":"Jacobson RD, Feldman EL. Antisense oligonucleotides for Duchenne muscular dystrophy: why no neurologist should skip this. JAMA Neurol. 2016;73(3):259\u201360. https:\/\/doi.org\/10.1001\/jamaneurol.2015.4011.","journal-title":"JAMA Neurol"},{"issue":"5","key":"587_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/nat.2017.0682","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A, Straub V, Hemmings R, Haas M, Schlosser-Weber G, Stoyanova-Beninska V, et al. Development of exon-skipping therapies for Duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucleic Acid Ther. 2017;27(5):251\u20139. https:\/\/doi.org\/10.1089\/nat.2017.0682.","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"587_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6010001","volume":"6","author":"T Aslesh","year":"2018","unstructured":"Aslesh T, Maruyama R, Yokota T. Skipping multiple exons to treat DMD\u2014promises and challenges. Biomedicines. 2018;6(1):1. https:\/\/doi.org\/10.3390\/biomedicines6010001.","journal-title":"Biomedicines"},{"issue":"1","key":"587_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0834-2","volume":"13","author":"Y Shimizu-Motohashi","year":"2018","unstructured":"Shimizu-Motohashi Y, Murakami T, Kimura E, Komaki H, Watanabe N. Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis. Orphanet J Rare Dis. 2018;13(1):93. https:\/\/doi.org\/10.1186\/s13023-018-0834-2.","journal-title":"Orphanet J Rare Dis"},{"key":"587_CR33","unstructured":"Medicaid enrollment changes following the ACA. MACPAC. 2022. www.macpac.gov\/subtopic\/medicaid-enrollment-changes-following-the-aca\/. Accessed 14 Jan 2025."},{"issue":"1","key":"587_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3233\/JND-140005","volume":"1","author":"JC Van Den Bergen","year":"2014","unstructured":"Van Den Bergen JC, Ginjaar HB, Essen AJ, Pangalila R, de Groot IJM, Wijkstra PJ, et al. Forty-five years of Duchenne muscular dystrophy in the Netherlands. J Neuromuscul Dis. 2014;1(1):99\u2013109.","journal-title":"J Neuromuscul Dis"},{"issue":"6","key":"587_CR35","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","volume":"56","author":"P Kieny","year":"2013","unstructured":"Kieny P, Chollet S, Delalande P, Magot A, Pereon Y, Verbe BP. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med. 2013;56(6):443\u201354. https:\/\/doi.org\/10.1016\/j.rehab.2013.06.002.","journal-title":"Ann Phys Rehabil Med"},{"issue":"7","key":"587_CR36","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","volume":"35","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochm\u00fcller H. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(7):643\u201353. https:\/\/doi.org\/10.1007\/s10654-020-00613-8.","journal-title":"Eur J Epidemiol"},{"issue":"23","key":"587_CR37","doi-asserted-by":"publisher","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","volume":"97","author":"J Broomfield","year":"2021","unstructured":"Broomfield J, Hill M, Guglieri M, Crowther M, Abrams K. Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis. Neurology. 2021;97(23):e2304\u201314. https:\/\/doi.org\/10.1212\/WNL.0000000000012910.","journal-title":"Neurology"},{"key":"587_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950651","volume":"13","author":"J Deng","year":"2022","unstructured":"Deng J, Zhang J, Shi K, Liu Z. Drug development progress in Duchenne Muscular Dystrophy. Front Pharmacol. 2022;13:950651. https:\/\/doi.org\/10.3389\/fphar.2022.950651.","journal-title":"Front Pharmacol"},{"key":"587_CR39","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","volume":"16","author":"S Guiraud","year":"2015","unstructured":"Guiraud S, Aartsma-Rus A, Vieira NM, Davies KE, van Ommen GJB, Kunkel LM. The pathogenesis and therapy of muscular dystrophies. Annu Rev Genom Hum Genet. 2015;16:281\u2013308. https:\/\/doi.org\/10.1146\/annurev-genom-090314-025003.","journal-title":"Annu Rev Genom Hum Genet"},{"issue":"2","key":"587_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.25122\/jml-2019-1003","volume":"12","author":"VL Purcarea","year":"2019","unstructured":"Purcarea VL. The impact of marketing strategies in healthcare systems. J Med Life. 2019;12(2):93\u20136. https:\/\/doi.org\/10.25122\/jml-2019-1003.","journal-title":"J Med Life"},{"key":"587_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10198-017-0932-4","volume":"19","author":"L Garattini","year":"2018","unstructured":"Garattini L, Padula A. Competition in pharmaceuticals: more product- than price- oriented? Eur J Health Econ. 2018;19:1\u20134. https:\/\/doi.org\/10.1007\/s10198-017-0932-4.","journal-title":"Eur J Health Econ"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-025-00587-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-025-00587-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-025-00587-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:57:27Z","timestamp":1760716647000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-025-00587-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["587"],"URL":"https:\/\/doi.org\/10.1007\/s40290-025-00587-6","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,20]]},"assertion":[{"value":"9 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availabilitiy"}},{"value":"The CMS datasets generated and analyzed during the current study are available from the Centers for Medicare & Medicaid Services at\u00a0. Accessed on March 31, 2023","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"YG: The conceptualization of study, literature review, research objectives, study design, data collection, data analysis, interpretation and discussion of study findings, and writing and reviewing the original draft of the manuscript. AL: Reviewing the final manuscript. JG: Data collection and reviewing the final manuscript. The authors confirm that the article has been reviewed and approved to be published.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}